TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
THOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ -- Amgen (AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...
Researchers reported on the effect of tezepelumab on global gene expression in patients with CRSwNP in the phase 3 WAYPOINT study. This is a syndicated post stub.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results